Therapeutic drug monitoring of flucytosine in a cardiac transplant patient receiving continuous veno‐venous hemofiltration and intermittent hemodialysis: A case report
- 1 February 2021
- journal article
- research article
- Published by Wiley in Transplant Infectious Disease
- Vol. 23 (4), e13575
- https://doi.org/10.1111/tid.13575
Abstract
Invasive candidiasis is one of the common infections in solid organ transplant recipients. Guidelines recommend echinocandins or liposomal amphotericin with consideration of flucytosine (5‐fluorocytosine; 5‐FC) as synergistic therapy for treatment of select deep‐seated Candida infections, including complex endovascular infections. Flucytosine undergoes extensive renal elimination; however, optimal dosing in patients with renal impairment, or those requiring renal replacement therapy (RRT), is not well‐established. We describe a case of a 60‐year old female who underwent orthotopic heart transplant complicated by Candida parapsilosis complex fungemia with mediastinitis and development of end‐stage renal disease requiring RRT. Flucytosine therapeutic drug monitoring was performed on continuous veno‐venous hemofiltration (CVVH) and intermittent hemodialysis (iHD) to guide appropriate dosing. Our results support 5‐FC doses of 25 mg/kg daily while undergoing CVVH with a low fluid replacement rate and 21 mg/kg post‐iHD or 17 mg/kg daily while receiving thrice weekly iHD.Keywords
This publication has 12 references indexed in Scilit:
- Candida infections in solid organ transplantation: Guidelines from the American Society of Transplantation Infectious Diseases Community of PracticeClinical Transplantation, 2019
- Clinical Practice Guideline for the Management of Candidiasis: 2016 Update by the Infectious Diseases Society of AmericaClinical Infectious Diseases, 2015
- Invasive fungal infections in solid organ transplant recipientsFuture Microbiology, 2012
- The AST Handbook of Transplant InfectionsPublished by Wiley ,2011
- Invasive Fungal Infections among Organ Transplant Recipients: Results of the Transplant‐Associated Infection Surveillance Network (TRANSNET)Clinical Infectious Diseases, 2010
- Antimicrobial Dosing Concepts and Recommendations for Critically Ill Adult Patients Receiving Continuous Renal Replacement Therapy or Intermittent HemodialysisPharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, 2009
- Antifungal serum concentration monitoring: an updateJournal of Antimicrobial Chemotherapy, 2007
- Adjustment of Antimicrobial Regimen in Critically Ill Patients Undergoing Continuous Renal Replacement TherapyYearbook of Intensive Care and Emergency Medicine, 2007
- Flucytosine: a review of its pharmacology, clinical indications, pharmacokinetics, toxicity and drug interactionsJournal of Antimicrobial Chemotherapy, 2000
- Flucytosine and Amphotericin B: Hemodialysis Effects on the Plasma Concentration and ClearanceAnnals of Internal Medicine, 1974